Twenty-eight new medicines added to DND list


Share post:

The Department of Health and Social Care (DHSC) has added further 28 new products to the list of ‘Drugs for which Discount is Not Deducted’ (DND) in Part II of the Drug Tariff from 1 August 2022.

PSNC said, “It will continue its work to assess whether other drugs and appliances fulfil the current DND entry requirements under either the ‘Group’ and ‘Individual item’ criteria and make applications to NHSBSA and DHSC, accordingly.”

The 28 products added to DND list on 1 August 2022:

  • Adrenaline (base) 500micrograms/0.5ml (1 in 1,000) solution for injection ampoules
  • Amantadine 50mg/5ml oral solution sugar free
  • Amiloride 5mg / Bumetanide 1mg tablets
  • Cabergoline 1mg tablets
  • Cabergoline 2mg tablets
  • Chloral hydrate 500mg/5ml oral solution
  • Doxepin 10mg capsules
  • Efmody 10mg modified-release capsules
  • Efmody 5mg modified-release capsules
  • Ephedrine hydrochloride 15mg tablets
  • Ephedrine hydrochloride 30mg tablets
  • Hydrocortisone 0.5% ointment
  • Liothyronine 10microgram capsules
  • Liothyronine 20microgram capsules
  • Liothyronine 5microgram capsules
  • Naproxen 125mg/5ml oral suspension sugar free
  • Ontozry 100mg tablets
  • Ontozry 12.5mg/25mg tablets treatment initiation pack
  • Ontozry 150mg tablets
  • Ontozry 200mg tablets
  • Ontozry 50mg tablets
  • Potassium dihydrogen phosphate 13.6% (potassium 10mmol/10ml) solution for infusion 10ml ampoules
  • Prednsiolone sodium phosphate 5mg suppositories
  • Procyclidine 10mg/2ml solution for injection ampoules
  • Rupatadine 10mg tablets
  • Tamoxifen 40mg tablets
  • Vazkepa 998mg capsules

A total of 529 products have been granted DND status following checks made by PSNC within the past 26 months.


Please enter your comment!
Please enter your name here

Current Issue June 2023

Related articles

MHRA grants authorisation for LEO Pharma’s Adtralza 2 mL pen solution

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution...

Grundon launches maiden UK-wide inhaler recycling programme

Grundon Waste Management has introduced what it claims to be the UK's first verified nationwide inhaler return and...

‘Record fine imposed on hydrocortisone manufacturers for dominant position abuse and 10,000% price increase’

The Competition Appeal Tribunal (CAT) has upheld the Competition and Markets Authority’s (CMA) findings against two pharmaceutical manufacturers...

Vision Report: Legal reforms, adequate funding imperative for success of community pharmacy

Achieving the community pharmacy vision necessitates legal adjustments and additional funding beyond recent boosts, the pharmacy vision document...